On November 19, 2026 Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology platform, reported strategy and business update and announces third quarter 2026 financial results.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Strategy update
Evaxion is refocusing its strategy to prioritize its immuno-oncology assets and capabilities, fully leveraging AI-Immunology in novel cancer target discovery and cancer vaccine development.
The aim is to maximize the value given clinical validation of the platform in personalized cancer vaccines with EVX-01 and the broader opportunity with off-the-shelf cancer vaccines in multiple indications through access to a wider diversity of novel antigens, including but not limited to endogenous retroviruses (ERVs).
Going forward, Evaxion will focus its R&D portfolio by:
Advancing off-the-shelf cancer vaccines EVX-04 and EVX-05 towards clinical development
Expanding personalized cancer vaccine EVX-01’s potential in multiple indications via partnerships
Continuing to identify new cancer vaccine targets for further development by mining novel sources from the dark genome
Working through partnerships on our preclinical portfolio of infectious disease assets
Completing validation on the autoimmune concepts we have developed with AI-Immunology for future partnerships
As a result of the refocused strategy, Evaxion will make some adjustments to its organization.
"We are refocusing our strategy on the unique capabilities of AI-Immunology in discovery and design of novel cancer vaccines. Evaxion’s AI-Immunology platform has recently been further validated by stronger clinical and translational datasets from the phase 2 trial with EVX-01 in advanced melanoma at a time when the entire landscape around personalized cancer vaccines has changed more positively. With the ability to also produce off-the-shelf cancer vaccines, we are maintaining strong operational momentum on all of our milestones for the year, tracking towards achieving the last one with the EVX-04 off-the-shelf vaccine clinical trial submission, as we re-focus our efforts towards immuno-oncology", says Helen Tayton-Martin, CEO of Evaxion.
Business highlights (since last quarterly update)
Presentation of three-year clinical outcome and immune data for personalized cancer vaccine EVX-01 at the ESMO (Free ESMO Whitepaper) Congress 2026 and additionally new phase 2 biomarker data at SITC (Free SITC Whitepaper) 2026
Announcing the upcoming presentation of new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML), at the ASH (Free ASH Whitepaper) 2026 Meeting
Winning the 2026 International Prix Galien Award for Best digital health solution for AI-Immunology
Our cash runway has been extended towards the end of 2027
Conference call and webcast
Evaxion’s executive management will host a conference call and webcast at 8.30am ET/14.30 CET today, presenting the business update and financial results as well as taking questions.
To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique PIN code. The call can be accessed 15 minutes prior to the start of the live event.
To join the webcast, please click on this link. The webcast recording will be available on our website shortly after the event.
Research & Development (R&D) update
Evaxion has a R&D pipeline of innovative vaccine candidates for both cancer and infectious diseases and has recently made progress in both areas.
Most notably, we have presented new phase 2 data for personalized cancer vaccine EVX-01, our most advanced pipeline asset, at both the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) and Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) congresses.
Designed with our AI-Immunology platform, EVX-01 is tailored to target the unique tumor profile and immune characteristics of each patient. It engages the patient’s immune system to attack the cancer by mounting a targeted response against tumor-specific neoantigens.
EVX-01 is intended for first-line treatment of multiple advanced solid cancer tumors and has, in the phase 2 trial, been evaluated as a treatment of advanced melanoma. The recent data shows an 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up.
The very high precision rate is another confirmation that AI-Immunology identifies and selects the most therapeutically relevant vaccine targets. Thus, the new data supports both EVX-01 as a promising personalized cancer vaccine and AI-Immunology as a validated technology for discovery and design of novel cancer treatments.
Further to the personalized approach, we are leveraging AI-Immunology to develop novel off-the-shelf cancer vaccines, including EVX-04 targeting AML. Developed with AI-Immunology, EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigens from the dark genome.
We are on track to file the application for a phase 1 trial with EVX-04 before the end of the year and continue to advance preclinical IND-enabling studies and expand the data package. We are very much looking forward to presenting new target validation data for EVX-04 at the important American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition in New Orleans, Louisiana, December 12-15, 2026.
Within infectious diseases we have achieved the milestone of designing and preclinically validating antigens to be included in EVX-B4, a novel vaccine candidate for Group A Streptococcus. As per our refocused strategy, we will only conduct future work on our infectious disease programs if funded by external partners and will continue to proactively pursue relevant partnership opportunities.
We have also recently presented AI-Immunology derived novel therapeutic concepts for autoimmune diseases. Our future activities in this space will be focused on concept validation for potential future partnerships.
Business development update
We remain active in multiple parallel partnership discussions based on external interest in both AI-Immunology and our R&D pipeline based on the strong clinical validation of our platform and as we continue to pursue our strategy of developing novel IO assets and strengthening our platform through strategic partnerships.
We were honored to receive the prestigious International Prix Galien Award for AI-Immunology as best digital health solution in October. The award is another strong external validation and recognition of the AI-Immunology platform in generating key data confirming the fact that AI-Immunology is a platform that delivers meaningful therapeutic product candidates. This is an important distinction with potential business partners.
Third quarter 2026 financial results
We have extended our cash runway towards the end of 2027 through utilization of our At-The-Market (ATM) equity program selling Evaxion shares resulting in gross proceeds of $2.2 million improving our cash at hand and equity.
Earlier in November, we filed an amendment to the registration statement on Form F-1 related to the 2025 debt settlement agreement with The European Investment Bank (EIB) with the US Securities and Exchange Commission.
The registration statement was originally filed in November 2025, as required under the agreement under which EIB converted debt to warrants, and relates solely to the possible resale by EIB of shares issuable upon exercise of those warrants. We are not conducting a capital raise.
The financial results for the third quarter 2026 were in line with expectations with a net loss of $3.5 million, compared to loss of $3.7 million in the second quarter 2026 and a profit of $4.6 million in the third quarter 2025.
Compared to same period last year where we recorded revenue from out-licensing EVX-B3 to MSD, no revenue has been recorded in Q3 2026, while we have reduced cost in the quarter compared to last year primarily relating to lower personnel expenses and capital market costs, and our net financial expenses reflects normalized financial income and expenses.
Research and development (R&D) expenses were $2.3 million for the third quarter 2026, aligned with second quarter 2026, and a reduction compared to third quarter last year, mainly due to reduced headcount.
General and administrative (G&A) expenses were $1.4 million for the quarter, level with second quarter 2026, and compared to $1.4 million in second quarter 2025. Compared to last year we have lower capital market cost compensated by higher business development costs.
Net financial expense of $0.1 million for the third quarter 2026 compared to net financial income of $1.3 million same quarter last year. The third quarter 2026 reflects our normalized business, and where Q3 last year was impacted by financial income from debt settlement agreement with EIB and financial expenses from a significant higher derivative liability.
Cash and cash equivalents as of September 30, 2026, were $13.3 million, compared to $14.0 million as of June 30, 2026, extending our current cash runway towards the end of 2027.
Total equity amounts to $8.1 million as of September 30, 2026, reflecting the net loss of the first nine months of 2026 and added the proceeds from ATM sales, when compared to $17.0 million as of December 31, 2025.
Evaxion A/S
(Unaudited) Consolidated statement of financial position data
(USD in thousands)
Sep 30,
2026 Dec 31,
2025
Cash and cash equivalents 13,274 23,234
Total assets 18,665 28,408
Total liabilities 10,523 11,369
Share capital 17,129 15,791
Other reserves 130,301 127,492
Accumulated deficit (139,288) (126,244)
Total equity 8,143 17,039
Total liabilities and equity 18,665 28,408
Evaxion A/S
(Unaudited) Consolidated statement of comprehensive loss data
(USD in thousands, except per share data)
Three Months Ended
Sep 30, Nine Months Ended
Sep 30,
2026 2025 2026 2025
Revenue - 7,492 - 7,528
Research and development (2,312) (3,092) (6,943) (7,415)
General and administrative (1,361) (1,377) (4,394) (5,295)
Operating profit/(loss) (3,673) 3,022 (11,338) (5,182)
Finance income 152 2,690 557 5,729
Finance expenses (212) (1,360) (730) (2,988)
Net profit/(loss) before tax (3,732) 4,352 (11,511) (2,442)
Income tax benefit 191 265 611 652
Net profit/(loss) for the period (3,541) 4,618 (10,899) (1,789)
Net loss attributable to shareholders of Evaxion A/S (3,541) 4,618 (10,899) (1,789)
Loss per share – basic and diluted (0.01) 0.01 (0.03) (0.01)
Number of shares used for calculation (basic and diluted) 431,856,012 318,041,649 422,013,554 289,792,967
(Press release, Evaxion, NOV 19, 2026, View Source [SID1234675022])